The Real-World Evidence (RWE) Solutions market is experiencing robust growth, projected to reach $828.46 million in 2025 and expand at a compound annual growth rate (CAGR) of 13% from 2025 to 2033. This significant expansion is driven by several key factors. The increasing adoption of RWE in regulatory decision-making, fueled by the need for more efficient and cost-effective drug development, is a primary driver. Furthermore, the rising availability of large, diverse datasets from electronic health records (EHRs), claims databases, and wearable devices provides rich sources of real-world data for analysis. Pharmaceutical companies and healthcare providers are actively investing in RWE solutions to improve clinical trial design, enhance post-market surveillance, and optimize treatment strategies, further bolstering market growth. The market is segmented by type (e.g., software, services) and application (e.g., drug development, post-market surveillance), each exhibiting unique growth trajectories influenced by specific technological advancements and regulatory landscapes. Competitive strategies among leading companies, such as Clinigen Group Plc, ICON Plc, and IQVIA Inc., focus on strategic partnerships, technological innovation, and expansion into new geographical markets. These companies are engaged in developing advanced analytical tools and data integration platforms to cater to growing demands for comprehensive RWE solutions. The North American market currently holds a substantial share, driven by robust regulatory frameworks and advanced healthcare infrastructure. However, other regions, particularly Asia Pacific, are expected to witness significant growth in the coming years due to increasing healthcare expenditure and technological advancements. The restraints on market growth are primarily related to data privacy concerns, regulatory hurdles in accessing and utilizing real-world data, and the need for robust data standardization across different sources. However, proactive measures like developing better data security protocols, clarifying regulatory guidelines, and investing in data harmonization initiatives are mitigating these challenges. The future of the RWE Solutions market hinges on continuous technological innovation, particularly in areas like artificial intelligence (AI) and machine learning (ML), which can enhance data analysis and generate valuable insights from complex datasets. Further growth will depend on fostering collaboration among stakeholders, including regulatory bodies, healthcare providers, and technology companies, to create a more conducive environment for RWE adoption.

Snapshot img

Real-World Evidence Solutions Market Analysis Report 2020-2024:

The real-world evidence solutions market size has the potential to grow by USD 697.92 mn during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by market landscape (oncology, immunology, cardiology, neurology, and others) and geography (Americas, EMEA, and APAC). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Clinigen Group Plc, ICON Plc, International Business Machines Corp., IQVIA Inc., Laboratory Corp. of America Holdings, Parexel International Corp., PerkinElmer Inc., Pharmaceutical Product Development LLC, SAS Institute Inc., and and Syneos Health Inc.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Real-World Evidence Solutions Market

Request a FREE sample now!

Market Competitive Analysis

The market is fragmented. Clinigen Group Plc, ICON Plc, International Business Machines Corp., IQVIA Inc., Laboratory Corp. of America Holdings, Parexel International Corp., PerkinElmer Inc., Pharmaceutical Product Development LLC, SAS Institute Inc., and and Syneos Health Inc. are some of the major market participants. Factors such as benefits of real-world evidence solutions will offer immense growth opportunities. To make the most of the opportunities, vendors should focus on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this real-world evidence solutions market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this real-world evidence solutions market analysis report provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

Clinigen Group Plc
ICON Plc
International Business Machines Corp.
IQVIA Inc.
Laboratory Corp. of America Holdings
Parexel International Corp.
PerkinElmer Inc.
Pharmaceutical Product Development LLC
SAS Institute Inc.
and Syneos Health Inc.

Real-World Evidence Solutions Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

The report offers an up-to-date analysis regarding the current Global market scenario, latest trends and drivers, and the overall market environment. Americas will offer several growth opportunities to market vendors during the forecast period. The integration of ehrs with electronic data collection systems will significantly influence real-world evidence solutions market's growth in this region.

52% of the market’s growth will originate from Americas during the forecast period. The US is the key market for real-world evidence solutions market in Americas. This report provides an accurate prediction of the contribution of all segments to the growth of the real-world evidence solutions market size.

Real-World Evidence Solutions Market: Key Highlights of the Report for 2020-2024

CAGR of the market during the forecast period 2020-2024
Detailed information on factors that will real-world evidence solutions market growth during the next five years
Precise estimation of the real-world evidence solutions market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the real-world evidence solutions industry across Americas, EMEA, and APAC
A thorough analysis of the market’s competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of real-world evidence solutions market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

    Real-World Evidence Solutions Market Scope




    Report Coverage


    Details




    Page number


    120




    Base year


    2019




    Forecast period


    2020-2024




    Growth momentum & CAGR


    Accelerate at a CAGR of 13%




    Market growth 2020-2024


    USD 697.92 million




    Market structure


    Fragmented




    YoY growth (%)


    10.53




    Regional analysis


    Americas, EMEA, and APAC




    Performing market contribution


    Americas at

The Real-World Evidence (RWE) in Healthcare market is experiencing robust growth, projected to reach $412.6 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 7.8% from 2025 to 2033. This expansion is fueled by several key drivers. The increasing adoption of RWE by regulatory bodies like the FDA for drug and medical device approvals accelerates market growth. This shift reflects a growing recognition of the value of real-world data in demonstrating clinical effectiveness and safety beyond traditional randomized controlled trials. Furthermore, the rise of digital health technologies, including electronic health records (EHRs) and wearable sensors, generates massive datasets ripe for analysis and insights, fostering innovation and expansion within the RWE market. The increasing prevalence of chronic diseases necessitates more comprehensive understanding of patient outcomes in real-world settings, bolstering the demand for RWE solutions. Major players like Anthem, IQVIA, and Oracle are heavily investing in RWE infrastructure and analytics, further strengthening market dynamics. Segmentation within the market includes services related to data collection, analysis, and interpretation, coupled with diverse datasets including EHRs, claims data, and patient registries used in drug development and medical device approval. Significant regional variations are expected. North America, driven by substantial investments in healthcare technology and robust regulatory frameworks, is anticipated to hold a dominant market share. However, Europe and Asia Pacific are also experiencing considerable growth, fueled by rising healthcare expenditure and increasing adoption of digital health solutions. The market faces certain restraints, such as data privacy concerns, interoperability challenges, and the need for standardized data collection protocols. Nonetheless, ongoing technological advancements and regulatory support are expected to mitigate these challenges and drive sustained expansion throughout the forecast period. The diverse applications of RWE, extending beyond clinical trials to post-market surveillance and personalized medicine, underpin the substantial long-term growth potential.

The Real-World Evidence (RWE) in Healthcare market is experiencing robust growth, projected to reach a substantial size driven by several key factors. The market's value, currently estimated at $434 million in 2025 (the base year), is poised for significant expansion, fueled by an 8.2% Compound Annual Growth Rate (CAGR) from 2025 to 2033. This growth is primarily attributed to the increasing adoption of RWE for regulatory submissions, drug development, and post-market surveillance. The rising availability of large healthcare datasets, coupled with advancements in analytics and data processing technologies, further accelerates market expansion. Pharmaceutical and biotech companies are increasingly leveraging RWE to gain valuable insights into treatment effectiveness, safety, and patient outcomes, optimizing clinical trials and resource allocation. Furthermore, the growing focus on personalized medicine and value-based care models is driving demand for RWE solutions that allow for more targeted and effective interventions. The competitive landscape is characterized by a mix of established players and emerging technology providers. Key players like Anthem, IQVIA, ICON, PPD, and others are investing heavily in RWE capabilities, expanding their service offerings and investing in strategic partnerships. The market segmentation, though not explicitly provided, likely includes services (data collection, analytics, consulting), technologies (software, platforms), and therapeutic areas (oncology, cardiology, etc.). While geographical data is missing, it's reasonable to assume a significant market share for North America and Europe given the high concentration of pharmaceutical companies and advanced healthcare infrastructure in these regions. The continued growth trajectory is expected to be influenced by factors like data privacy regulations, interoperability challenges, and the need for standardized RWE methodologies. However, the overall positive growth trend suggests a bright future for the RWE market in healthcare.

The global Real-World Evidence (RWE) market is projected to reach a significant valuation by 2033, growing at a steady CAGR of 8.2%. This growth can be attributed to the increasing demand for RWE in drug development and approval processes, as well as in the development and approval of medical devices. The market is segmented into various types of services and data sets, with key players including Anthem, IQVIA, ICON, PPD, and Clinigen Group. Drivers of the RWE market include the rising adoption of value-based healthcare, the increasing availability of electronic health records (EHRs), and the growing focus on patient-centric outcomes. The trend towards personalized medicine is also expected to contribute to the market's growth, as RWE can provide valuable insights into patient-specific treatment plans. Despite the significant opportunities, the market may face restraints such as data privacy and security concerns, as well as the need for robust data quality and analytics capabilities.

These are peer-reviewed supplementary materials for the article 'Adherence, duration and healthcare costs in a real-world population of patients with acromegaly' published in the Journal of Comparative Effectiveness Research.Table A: List of CPT and ICD codes for hypophysectomy and stereotactic radiosurgeryTable B: List of ICD-9 codes and ICD-10 codes for comorbidities of interestAim: The aim of this study was to describe treatment patterns among patients with acromegaly who are newly treated with acromegaly medical therapy. Materials &methods: Data from IQVIA Pharmetrics Plus R ?Database from 1 January 2013 to 30 June 2023 were used to identify patientswith acromegaly who started a new acromegaly medical therapy and observe their treatment patterns. Patients were required to have at least 12 months of data without any acromegaly therapy (medication or surgery) prior to the index date and at least 6 months of follow-up. Comorbidities were measured during the baseline period. Adherence, persistence, medication and switching were measured during follow-up. Results: A total of 453 patients with acromegaly who were newly treated with acromegaly medical therapy and had no evidence of acromegaly therapy for at least 12 months were identified. Among these patients, 46.1% (n = 206) were treated with cabergoline as their index treatment, 24.5% (n = 111) with injectable octreotide, 15.0% (n = 68) with lanreotide, 5.5% (n = 25) with bromocriptine, 4.9% (n = 22) with pegvisomant, 2.2% (n = 10) with pasireotide, 1.1% (n = 5) with oral octreotide, 0.4% (n = 2) with cabergoline + octreotide, and 0.2% (n = 1) with cabergoline + lanreotide. By the end of the follow-up period, 54.3% (n = 246) were not on any treatment, 19.6% (n = 89) remained on the index treatment, and the remaining 26.0% (n = 118) switched to another treatment. Conclusion: This study contributed to the growing evidence that patients with acromegaly are not well-served by current therapeutic options, as indicated by high rates of treatment discontinuation, switching and add-on therapy. However, treatment switching and add-on therapy represent ongoing efforts to optimize patient care toward more effective and tolerable treatments. Expanded treatment options may serve an unmet need in this patient population.

Note: This is based on information licensed from IQVIA: CompuScript for the period of January 2018 to December 2021 reflecting estimates of real-world activity. All rights reserved.